Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harte Hanks (HHS) EBITDA Margin (2016 - 2025)

Harte Hanks (HHS) has disclosed EBITDA Margin for 16 consecutive years, with 0.56% as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 0.56% in Q2 2025 year-over-year; TTM through Jun 2025 was 2.28%, a 150.0% increase, with the full-year FY2024 number at 0.11%, down 127.0% from a year prior.
  • EBITDA Margin was 0.56% for Q2 2025 at Harte Hanks, down from 0.8% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 55.94% in Q4 2022 to a low of 3.38% in Q1 2021.
  • A 5-year average of 9.56% and a median of 5.01% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: soared 3477bps in 2021, then tumbled -5762bps in 2023.
  • Harte Hanks' EBITDA Margin stood at 25.57% in 2021, then soared by 119bps to 55.94% in 2022, then crashed by -103bps to 1.68% in 2023, then skyrocketed by 148bps to 0.8% in 2024, then plummeted by -170bps to 0.56% in 2025.
  • Per Business Quant, the three most recent readings for HHS's EBITDA Margin are 0.56% (Q2 2025), 0.8% (Q4 2024), and 6.16% (Q3 2024).